- Home
- SCNX vs IGC Comparison
SCNX vs IGC Comparison
Compare SCNX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | IGC |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 31.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SCNX | IGC |
|---|---|---|
| Price | $0.53 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | ★ 1.6M | 975.0K |
| Earning Date | 11-13-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $653,391.00 | ★ $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.88 | N/A |
| 52 Week Low | $0.46 | $0.25 |
| 52 Week High | $6.41 | $0.50 |
Technical Indicators
Market Signals| Indicator | SCNX | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 46.99 |
| Support Level | $0.51 | $0.28 |
| Resistance Level | $0.54 | $0.31 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 36.36 | 36.24 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.